Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib and Lacutoclax in B-Cell Malignancies
NCT07609862Phase 2Recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of rocbrutinib, lacutoclax in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), sponsored by Lupeng Pharmaceutical. Started Jul 2026; status: recruiting.
02
Drugs
rocbrutiniblacutoclax
03
Conditions
mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)Waldenström macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07609862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609862.